With a Buy rating, B of A Securities initiated coverage on AlloVir Inc ALVR. The price target seems to have been set at $17.00 for AlloVir. In the second quarter, AlloVir showed an EPS of $0.48, compared to $0.69 from the year-ago quarter. The current stock performance of AlloVir shows a 52-week-high of $10.22 and a 52-week-low of $2.42. Moreover, at the end of the last trading period, the closing price was at $2.47.